These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 16585158)

  • 21. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
    Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
    Passardi A; Maltoni R; Milandri C; Cecconetto L; Massa I; Zoli W; Tesei A; Fabbri F; Nanni O; Amadori D
    Oncology; 2007; 72(1-2):118-24. PubMed ID: 18004083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
    Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
    Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
    Nukatsuka M; Fujioka A; Nakagawa F; Oshimo H; Kitazato K; Uchida J; Sugimoto Y; Nagayama S; Fukushima M
    Int J Oncol; 2004 Dec; 25(6):1531-6. PubMed ID: 15547687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
    Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
    J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of combination therapy of UFT-E with low-dose CDDP for patients with advanced recurrent breast cancer].
    Ito T; Yamada M; Tanemura H; Oshita H; Asano M; Saji S
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1575-80. PubMed ID: 9725051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
    Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
    Nio Y; Iguchi C; Kodama H; Itakura M; Hashimoto K; Koike M; Toga T; Maruyama R; Fukushima M
    Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental study of the effect of combined treatment of UFT with CDDP on human solid tumor-xenografts in nude mice].
    Yamada Y; Saito H; Oie S; Takechi T; Nakano K; Takeda S
    Gan To Kagaku Ryoho; 1990 Jul; 17(7):1327-31. PubMed ID: 2114827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
    Cruz-Munoz W; Man S; Xu P; Kerbel RS
    Cancer Res; 2008 Jun; 68(12):4500-5. PubMed ID: 18559492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
    Kiman K; Suzuki S; Satomi T; Sakonji M; Nihei M; Tanaka T; Kimijima I; Abe R
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2445-52. PubMed ID: 7944490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
    Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
    Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system.
    Takahashi Y; Yamashita K; Endo Y; Sasaki T; Mai M
    Surg Today; 2004; 34(10):855-9. PubMed ID: 15449156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antitumor effect of intermittent oral administration of UFT against human rectal cancer xenografted in nude mice].
    Yamada K; Takao S; Ishizawa T; Shimazu H
    Gan To Kagaku Ryoho; 1988 Feb; 15(2):291-6. PubMed ID: 3124769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer.
    Smith IE
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):82-5. PubMed ID: 10442370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
    Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
    Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models.
    Streck CJ; Dickson PV; Ng CY; Zhou J; Gray JT; Nathwani AC; Davidoff AM
    Clin Cancer Res; 2005 Aug; 11(16):6020-9. PubMed ID: 16115947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.